Canine Interleukin 4,IL-4 ELISA Kit
- Known as:
- Canine Interleukin 4,Interleukin-4 Enzyme-linked immunosorbent assay test Kit
- Catalog number:
- E0002Ca
- Product Quantity:
- 48T
- Category:
- Elisa Kits
- Supplier:
- JING
- Gene target:
- Canine Interleukin 4 IL-4 ELISA Kit
Related genes to: Canine Interleukin 4,IL-4 ELISA Kit
- Gene:
- IL4 NIH gene
- Name:
- interleukin 4
- Previous symbol:
- -
- Synonyms:
- BSF1, IL-4, BCGF1, BCGF-1, MGC79402
- Chromosome:
- 5q31.1
- Locus Type:
- gene with protein product
- Date approved:
- 1988-08-10
- Date modifiied:
- 2016-10-05
- Gene:
- TLR2 NIH gene
- Name:
- toll like receptor 2
- Previous symbol:
- -
- Synonyms:
- TIL4, CD282
- Chromosome:
- 4q31.3
- Locus Type:
- gene with protein product
- Date approved:
- 1998-06-25
- Date modifiied:
- 2016-10-25
Related products to: Canine Interleukin 4,IL-4 ELISA Kit
Related articles to: Canine Interleukin 4,IL-4 ELISA Kit
- Interleukin (IL)-13 can modulate tumor immunosurveillance. The interplay between IL-13 and immunotherapy outcomes has not been well elucidated. - Source: PubMed
Publication date: 2026/05/04
Fountzilas ElenaKurzrock RazelleNishizaki DaisukeSzabo AnikoPabla SarabjotDePietro PaulJensen Taylor JKato ShumeiTsimberidou Apostolia-Maria - Rademikibart (CBP-201) is a human monoclonal antibody with higher binding affinity to IL-4Rα compared to dupilumab. Dupilumab is a first-generation interleukin-4 receptor alpha (IL-4Rα) inhibitor for treating IL-4Rα-dependent inflammatory disorders, including several dermatologic and respiratory conditions. Rademikibart, however, demonstrated better inhibition of STAT6 intracellular signaling and similar potency in inhibiting both IL-4 induced TARC release and IL-4 induced B cell activation. To further characterize the molecular function of rademikibart and its differentiation from dupilumab, we determined the crystal structure of the rademikibart fragment antigen binding (Fab) bound to IL-4Rα at 2.71 Å resolution and compared this to the 2.82 Å resolution structure of dupilumab Fab bound to IL-4Rα. The rotation angle between dupilumab and rademikibart bound to IL-4Rα is 54.88°. This rotation enables the binding epitopes of rademikibart, but not dupilumab, on IL-4Rα to overlap more closely with the conserved binding interface naturally utilized by IL-4 and IL-13 cytokines. Molecular dynamics (MD) studies on rademikibart and dupilumab bound to IL-4Rα examined the stability of the complexes and effects of amino acid mutations on receptor complex formation. MD simulations demonstrated that the third interface loop (residues 145 to 153 in domain 2) of IL-4Rα interacts directly with rademikibart, which is absent in the dupilumab/IL-4Rα complex. This finding is confirmed by increased hydrogen bond interactions at the interface between rademikibart and IL-4Rα, demonstrating superior binding energy for rademikibart. Through analysis of the x-ray crystallography structures, MD-equilibrated structures, and computational point-mutation analysis of rademikibart, we identified residue Y50 and R55 of the light chain and R97, R99, and Y101 of the heavy chain of rademikibart as key residues interacting with IL-4Rα's third interface loop. Our data provides a molecular and structural rationale for the enhanced IL-4Rα inhibition by rademikibart over dupilumab, confirming rademikibart as an optimized second-generation IL-4Rα inhibitor. - Source: PubMed
Publication date: 2026/04/13
Shi YuanjunNolden KelseyHo MinhLi HaoteBatista Victor SCollazo RaúlBunick Christopher G - Allergic airway inflammation, a hallmark of asthma, is commonly driven by environmental allergens such as house dust mite (HDM). This study examined the protective effects of caraway (Carum carvi) and marjoram (Origanum majorana) extracts in a rat model of HDM-induced allergic airway inflammation. Daily HDM intranasal administration was applied over four weeks, with or without concurrent oral administration of the herbal extracts. Both treatments significantly reduced airway inflammation, total serum IgE, and pro-inflammatory cytokines (IL-6 and TNF-α), as well as the regulatory cytokine IL-10 in bronchoalveolar lavage fluid (BALF). RT-qPCR revealed a marked downregulation of Th2-associated cytokines (IL-4, IL-5, and IL-13) and the mucus-related gene Muc5ac, along with the restoration of the regulatory marker Foxp3. Consistently, ELISA analysis of BALF showed partial recovery of the Th1 cytokine IFN-γ. Western blotting confirmed reduced protein expression of NF-κB and STAT6 in treated groups. Histological examination showed notable improvement in lung architecture. Collectively, these findings suggest that caraway and marjoram attenuate HDM-induced airway inflammation through immunomodulatory and anti-inflammatory mechanisms, supporting their potential as complementary therapeutic agents for allergic asthma. - Source: PubMed
Publication date: 2026/04/20
Refaat Ahmed MMohammed Honyda SAli FaroukMohamed HebaAbdallah RaniaAbdel-Salam Bahaa K A - PARP14, a pivotal mono-ADP-ribosyltransferase, has been reported to promote the development of inflammatory diseases via IL-4/STAT6/Th2 and IL-6/STAT3/Th17 signaling axes, making it an attractive therapeutic target for related disorders. Herein, we employed structure-based virtual screening and subsequent structural optimization to identify a series of novel PARP14 inhibitors featuring a phthalazinone scaffold. Among them, compound exhibited strong PARP14 inhibitory activity (IC = 3.03 nM), exceptional selectivity, and robust suppression of PARP14-mediated mono-ADP-ribosylation (MARylation) in cell-based assays. In a dinitrochlorobenzene (DNCB)-induced atopic dermatitis (AD)-like mouse model, significantly attenuated skin lesions and effectively decreased the expression of key inflammatory factors, including IL-4, IL-13, IgE, and IL-17A, demonstrating superior efficacy compared with RBN-3143 and Upadacitinib. In short, our findings establish as a novel and potent PARP14 inhibitor with promising therapeutic potential against AD. - Source: PubMed
Publication date: 2026/04/20
Wu ShiqiCong KaiyuanLiu JingQu LeZeng XiaorongKong XiangyingLi ZiyueLou ShaoxueWei PingShao LiGu HongfengZhao YanXu QinlongChu ZhaoxingHe GuangweiZhu QihuaXu YungenZou Yi - Induced membrane technique (IMT), a novel approach for reconstructing critical-size bone defect, encounters the challenge of lengthy mineralization time after bone grafting. This study is to explore the effect of Naringin on M2 macrophage polarization-mediated osteogenesis in the induced membrane's bone graft area. - Source: PubMed
Publication date: 2026/04/15
Li ShuyuanYe JinfeiYang DawenCai QunbinZeng ZhanpengZhou Qishi